Abstract
After hepatocellular carcinoma, intrahepatic cholangiocarcinoma (ICC) is the second most common primary hepatic malignancy. The etiology of ICC in most patients is not known, but its incidence is on the rise worldwide. There are 3 morphologic subtypes of ICC that can be characterized on cross-sectional imaging, mass forming, periductal infiltrating, and intraductal growth; and the radiographic characteristics of ICC may vary based on the subtype. Complete surgical resection remains the only potentially curative option for patients with ICC. Routine lymphadenectomy at the time of surgical resection should be strongly considered, because lymph node status provides important prognostic information. After surgery, the 5-year survival rate for ICC remains poor at only 25% to 35% in most series. Although numerous clinical trials have been conducted using a variety of chemotherapy regimens to treat ICC, systemic options for ICC remain limited. Doublet gemcitabine and cisplatin therapy is currently considered the standard-of-care first-line therapy for patients with advanced disease. Because ICC is typically confined to the liver and systemic chemotherapy traditionally has had only limited efficacy, there has been increasing interest in locoregional therapy. Although locoregional therapy may include intra-arterial therapies, stereotactic radiotherapy, hepatic artery pump therapy, or ablation, most data are limited. The purpose of this article was to provide a multidisciplinary appraisal of the current therapeutic approaches to ICC.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 3929-3942 |
| Number of pages | 14 |
| Journal | Cancer |
| Volume | 119 |
| Issue number | 22 |
| DOIs | |
| State | Published - Nov 15 2013 |
Fingerprint
Keywords
- chemotherapy
- imaging
- intrahepatic cholangiocarcinoma
- locoregional
- multidisciplinary
- resection
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Multidisciplinary approaches to intrahepatic cholangiocarcinoma. / Maithel, Shishir K.; Clark Gamblin, T.; Kamel, Ihab R; Corona Villalobos, Celia; Thomas, Melanie; Pawlik, Timothy M.
In: Cancer, Vol. 119, No. 22, 15.11.2013, p. 3929-3942.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Multidisciplinary approaches to intrahepatic cholangiocarcinoma
AU - Maithel, Shishir K.
AU - Clark Gamblin, T.
AU - Kamel, Ihab R
AU - Corona Villalobos, Celia
AU - Thomas, Melanie
AU - Pawlik, Timothy M.
PY - 2013/11/15
Y1 - 2013/11/15
N2 - After hepatocellular carcinoma, intrahepatic cholangiocarcinoma (ICC) is the second most common primary hepatic malignancy. The etiology of ICC in most patients is not known, but its incidence is on the rise worldwide. There are 3 morphologic subtypes of ICC that can be characterized on cross-sectional imaging, mass forming, periductal infiltrating, and intraductal growth; and the radiographic characteristics of ICC may vary based on the subtype. Complete surgical resection remains the only potentially curative option for patients with ICC. Routine lymphadenectomy at the time of surgical resection should be strongly considered, because lymph node status provides important prognostic information. After surgery, the 5-year survival rate for ICC remains poor at only 25% to 35% in most series. Although numerous clinical trials have been conducted using a variety of chemotherapy regimens to treat ICC, systemic options for ICC remain limited. Doublet gemcitabine and cisplatin therapy is currently considered the standard-of-care first-line therapy for patients with advanced disease. Because ICC is typically confined to the liver and systemic chemotherapy traditionally has had only limited efficacy, there has been increasing interest in locoregional therapy. Although locoregional therapy may include intra-arterial therapies, stereotactic radiotherapy, hepatic artery pump therapy, or ablation, most data are limited. The purpose of this article was to provide a multidisciplinary appraisal of the current therapeutic approaches to ICC.
AB - After hepatocellular carcinoma, intrahepatic cholangiocarcinoma (ICC) is the second most common primary hepatic malignancy. The etiology of ICC in most patients is not known, but its incidence is on the rise worldwide. There are 3 morphologic subtypes of ICC that can be characterized on cross-sectional imaging, mass forming, periductal infiltrating, and intraductal growth; and the radiographic characteristics of ICC may vary based on the subtype. Complete surgical resection remains the only potentially curative option for patients with ICC. Routine lymphadenectomy at the time of surgical resection should be strongly considered, because lymph node status provides important prognostic information. After surgery, the 5-year survival rate for ICC remains poor at only 25% to 35% in most series. Although numerous clinical trials have been conducted using a variety of chemotherapy regimens to treat ICC, systemic options for ICC remain limited. Doublet gemcitabine and cisplatin therapy is currently considered the standard-of-care first-line therapy for patients with advanced disease. Because ICC is typically confined to the liver and systemic chemotherapy traditionally has had only limited efficacy, there has been increasing interest in locoregional therapy. Although locoregional therapy may include intra-arterial therapies, stereotactic radiotherapy, hepatic artery pump therapy, or ablation, most data are limited. The purpose of this article was to provide a multidisciplinary appraisal of the current therapeutic approaches to ICC.
KW - chemotherapy
KW - imaging
KW - intrahepatic cholangiocarcinoma
KW - locoregional
KW - multidisciplinary
KW - resection
UR - http://www.scopus.com/inward/record.url?scp=84887087327&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84887087327&partnerID=8YFLogxK
U2 - 10.1002/cncr.28312
DO - 10.1002/cncr.28312
M3 - Article
C2 - 23963845
AN - SCOPUS:84887087327
VL - 119
SP - 3929
EP - 3942
JO - Cancer
JF - Cancer
SN - 0008-543X
IS - 22
ER -